ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0057

Molecular Profiling of Radiographic Axial Spondyloarthritis Patients Reveals an Association Between Innate and Adaptive Cell Populations and Therapeutic Response to Adalimumab

Rita Torres1, Daniel Sobral2, Ana Fernandes3, Atlas Sardoo4, Miguel Bernardes5, Patrícia Pinto6, Helena Santos7, João Gomes8, Jose Tavares-Costa9, José Silva10, João Dias11, Alexandra Bernardo5, Jean Gailard12, Jean Armengaud13, Vladimir Benes14, Lúcia Domingues15, Sara Maia16, Jaime Branco17, Ana Varela18 and Fernando Santos19, 1Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, 2Faculdade Ciências e Tecnologia, Lisboa, Lisboa, Portugal, 3Instituto de Tecnologia Química e Biológica, Lisboa, Portugal, 4CEDOC, NOVA Medical School, UNL, Lisboa, Lisboa, Portugal, 5Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, 6Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal, 7Portuguese Institute of Rheumatology, Lisbon, Portugal, 8Hospital Egas Moniz, Lisboa, Lisboa, Portugal, 9Rheumatology Department - Unidade Local de Saude do Alto Minho, Ponte de Lima, Portugal, 10Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, 11Centro Hospitalar Médio Tejo, Abrantes, Portugal, 12Centre dénergie atomique; Service de Pharmacologie et Immunoanalyse (SPI), Paris, France, 13Service de Pharmacologie et Immunoanalyse (SPI), Paris, France, 14The European Molecular Biology Laboratory, Heidelberg, Germany, 15CEDOC - Chronic Diseases Research Center - Nova Medical School|Faculdade de Ciências Médicas, Lisboa, Lisboa, Portugal, 16NOVA Medical School, Nova University of Lisbon, Lisboa, Lisboa, Portugal, 17EpiDoC Unit, CEDOC, Nova Medical School, Comprehensive Health Research Centre (CHRC), Lisbon, Portugal, 18Instituto Tecnologia Química e Biológica; Universidade NOVA de Lisboa, Lisboa, Lisboa, Portugal, 19Hospital Egas Moniz, Lisboa, Portugal

Meeting: ACR Convergence 2021

Keywords: Adhesion, Adhesion molecules, Ankylosing spondylitis (AS), Anti-TNF Drugs

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: The response to treatment in spondylarthropaties is heterogeneous, due to factors yet to be better described. For that reason, it is important to find tools that might help clinicians to decide what is the best available therapeutic option for each patient.

The goal of this study is to use comprehensive molecular profiling to characterize clinical response to therapy in a real-world setting. Specifically, to identify molecular biomarkers differentiating good responders and non-responders to TNF inhibitors (TNFi) treatment, using adalimumab, in radiographic axial spondyloarthritis | ankylosing spondylitis (r-axSpA|AS) patients context.

Methods: Whole-blood mRNA and plasma proteins were measured in a cohort of biologic naïve r-axSpA|AS patients (n = 35) from the Bioefficacy study (Biomarkers identification of anti-TNF alpha agent efficacy in AS patients using RNA sequencing and mass spectrometry), pre and post (14 weeks) TNFi treatment using adalimumab. Response to treatment was categorized according to ASAS20. Results of differential expression analysis were used to identify the most enriched pathways and in predictive models to distinguish responses to TNFi.

Results: A treatment-related signature, independent of the type of response, suggests a reduction in inflammatory disease activity. We found genes and proteins robustly differentially expressed between baseline and week 14 in responders, including the GWAS AS-associated genes TNFRSF1A, FCGR2A, TYK2, TBKBP1, IL1R1, IL6R, ICOSLG, IL7R, HHAT and LTBR. Moreover, CRP and HP proteins showed strong and early decrease in the plasma of AS patients, while a cluster of apolipoproteins (APO1, APO2, APO3) showed an increased expression at week 14. Good responders to TNFi treatment tend to have higher expression of innate immunity genes at baseline, and lower expression of markers associated with adaptive immunity, particularly B-cells. A logistic regression model incorporating ASDAS-CRP, gender and Gene x, the top differentially expressed gene at baseline between responders and non-responders, enabled an accurate prediction of response to adalimumab in our cohort (AUC=0.97).

Conclusion: Differences in disease activity and/or innate/adaptive immune cell type composition at baseline may be a major contributor to response to adalimumab in r-axSpA|AS. Alternatively, a model including clinical and gene expression variables could be considered, particularly in patients with mild disease activity.


Disclosures: R. Torres, None; D. Sobral, None; A. Fernandes, None; A. Sardoo, None; M. Bernardes, Lilly, 1, Janssen, 1, Abbvie, 1; P. Pinto, None; H. Santos, None; J. Gomes, None; J. Tavares-Costa, None; J. Silva, None; J. Dias, None; A. Bernardo, None; J. Gailard, None; J. Armengaud, None; V. Benes, None; L. Domingues, None; S. Maia, None; J. Branco, None; A. Varela, None; F. Santos, None.

To cite this abstract in AMA style:

Torres R, Sobral D, Fernandes A, Sardoo A, Bernardes M, Pinto P, Santos H, Gomes J, Tavares-Costa J, Silva J, Dias J, Bernardo A, Gailard J, Armengaud J, Benes V, Domingues L, Maia S, Branco J, Varela A, Santos F. Molecular Profiling of Radiographic Axial Spondyloarthritis Patients Reveals an Association Between Innate and Adaptive Cell Populations and Therapeutic Response to Adalimumab [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/molecular-profiling-of-radiographic-axial-spondyloarthritis-patients-reveals-an-association-between-innate-and-adaptive-cell-populations-and-therapeutic-response-to-adalimumab/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/molecular-profiling-of-radiographic-axial-spondyloarthritis-patients-reveals-an-association-between-innate-and-adaptive-cell-populations-and-therapeutic-response-to-adalimumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology